Get the Stockscreener App
3.91
2.36%
0.09
After Hours:
3.86
-0.05
-1.28%
Sight Sciences Inc stock is traded at $3.91, with a volume of 185.66K.
It is up +2.36% in the last 24 hours and up +6.54% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
See More
Previous Close:
$3.82
Open:
$3.82
24h Volume:
185.66K
Relative Volume:
0.60
Market Cap:
$211.16M
Revenue:
$77.36M
Net Income/Loss:
$-38.43M
P/E Ratio:
-5.2781
EPS:
-0.7408
Net Cash Flow:
$-29.92M
1W Performance:
+12.36%
1M Performance:
+6.54%
6M Performance:
+8.61%
1Y Performance:
+55.16%
1-Day Range:
$3.82
$3.96
1-Week Range:
$3.378
$3.96
52-Week Range:
$2.3998
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
3.91 | 206.30M | 77.36M | -38.43M | -29.92M | -0.7408 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-08-25 | Upgrade | Lake Street | Hold → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight Sciences wins $34M patent ruling against Alcon - MSN
KCK LTD. Significantly Reduces Stake in Sight Sciences Inc - GuruFocus
SGHT: Momentum builds for interventional glaucoma and dry eye, with innovation and adoption accelerating - TradingView — Track All Markets
If You Invested $1,000 in Sight Sciences, Inc. (SGHT) - Stock Titan
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Sight Sciences CLO Hayden sells shares worth $48,851 By Investing.com - Investing.com India
Sight Sciences CLO Hayden sells shares worth $48,851 - Investing.com
Sight Sciences CFO Rodberg sells $25,670 in shares - Investing.com
Sight Sciences CFO Rodberg sells $25,670 in shares By Investing.com - Investing.com Canada
Sight Sciences (NASDAQ: SGHT) CFO sells 7,231 shares to cover RSU taxes - Stock Titan
Sight Sciences (SGHT) legal chief sells 13,761 shares for RSU tax obligations - Stock Titan
KCK Ltd. reports 1.44M shares in Sight Sciences (SGHT) — 2.7% stake - Stock Titan
Bull Bear: Does ITRI offer margin of safetyWeekly Profit Analysis & Smart Investment Allocation Tips - baoquankhu1.vn
Citi Maintains Sight Sciences(SGHT.US) With Hold Rating, Cuts Target Price to $4.35 - Moomoo
Affiliate notice: SGHT (NASDAQ: SGHT) proposes common-share sale tied to vesting - Stock Titan
SGHT (NASDAQ: SGHT) sale notice: 13,761 restricted shares vesting - Stock Titan
Published on: 2026-04-05 14:40:16 - baoquankhu1.vn
SGHT SEC FilingsSight Sciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Taylor, EVP, operations & R&D, sells $10.6k in Sight Sciences (SGHT) - Investing.com Australia
Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells 8,168 Shares of Stock - MarketBeat
Taylor, EVP, operations & R&D, sells $10.6k in Sight Sciences (SGHT) By Investing.com - Investing.com South Africa
Sight Sciences (NASDAQ:SGHT) EVP Brenton Taylor Sells 2,869 Shares - MarketBeat
Sight Sciences (NASDAQ:SGHT) CEO Sells 29,244 Shares - MarketBeat
Sight Sciences CEO Badawi sells $108k in shares By Investing.com - Investing.com India
[Form 4] Sight Sciences, Inc. Insider Trading Activity - Stock Titan
Sight Sciences CEO Badawi sells $108k in shares - Investing.com
Sight Sciences (SGHT) CTO tax-related sale of 8,168 shares disclosed - Stock Titan
Sight Sciences (SGHT) EVP Brenton sells 2,869 shares for RSU tax obligations - Stock Titan
Sight Sciences executive plans $90K stock sale - National Today
Alison Bauerlein plans sale of 25,874 shares (SGHT) - Stock Titan
Insider sale notice: SGHT (NASDAQ: SGHT) 8,168 restricted shares - Stock Titan
SGHT PE Ratio & Valuation, Is SGHT Overvalued - Intellectia AI
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - The Manila Times
Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to Be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - 富途牛牛
SGHT (NASDAQ: SGHT) files Form 144 to sell 29,244 vested shares - Stock Titan
Proposed share sales at SGHT (NASDAQ: SGHT) include 2,293 and 576 shares - Stock Titan
Aug Rallies: Is Sight Sciences Inc a top pick in the sectorTrade Risk Summary & Target Return Focused Stock Picks - baoquankhu1.vn
Sight Sciences wins $34M in Alcon patent case, ongoing royalty By Investing.com - Investing.com South Africa
Sight Sciences Wins $34 Million Patent Infringement Case Against Alcon, Secures Ongoing Royalties Through 2028 - Minichart
Sight Sciences wins $34M in Alcon patent case, ongoing royalty - Investing.com Australia
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th - GlobeNewswire
Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud - Law360
Lake Street Maintains Sight Sciences(SGHT.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Published on: 2026-03-31 02:42:17 - baoquankhu1.vn
Sight Sciences U.S. district court issued order on post-trial motions in patent infringement case against Alcon originally filed on Sep 16, 2021 - marketscreener.com
Sight Sciences U.S. District Court Issued Order On Post-Trial Motions In Patent Infringement Case Against Alcon Originally Filed On Sep 16, 2021 - TradingView
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sight Sciences Inc Stock (SGHT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HAYDEN JEREMY B. | Chief Legal Officer |
Apr 06 '26 |
Sale |
3.55 |
13,761 |
48,852 |
369,770 |
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):